A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
11/2001
11/22/2001	WO2001088129A1 Anti-angiogenic polypeptides
11/22/2001	WO2001088119A1 Novel g protein-coupled receptor protein and dna thereof
11/22/2001	WO2001088095A1 Microorganisms for treatment or prevention of obesity and diabetes mellitus, and pharmaceutical composition containing the same
11/22/2001	WO2001087889A1 Crf receptor antagonists and methods relating thereto
11/22/2001	WO2001087886A1 Crf receptor antagonists and methods relating thereto
11/22/2001	WO2001087882A2 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
11/22/2001	WO2001087881A1 Piperidyindoles as serotonin receptor ligands
11/22/2001	WO2001087862A2 Biologically active 4h-benzo[1,4]oxazin-3-ones
11/22/2001	WO2001087861A2 Methods of treatment using benzoxazinones as peroxisome proliferator activated receptor gamma modulators
11/22/2001	WO2001087860A2 Novel benzoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment
11/22/2001	WO2001087850A1 Pyridazine derivative elevating pdhactivity
11/22/2001	WO2001087849A2 Modulators of tnf- alpha signaling
11/22/2001	WO2001087843A1 Compounds for treating disorders where a decreased level of plasma ffa is desired
11/22/2001	WO2001087841A1 Novel polymorph v of torasemide
11/22/2001	WO2001087840A1 Propanoic acid derivatives as integrin receptor antagonists
11/22/2001	WO2001087829A1 Bisacylguanidine
11/22/2001	WO2001087823A1 Novel aryl, alkenyl, and alkynl 4-dedimethylaminotetracycline derivatives
11/22/2001	WO2001087810A1 Methods for the production of d-chiro-inositol and the use of d-chiro-inositol obtained therefrom
11/22/2001	WO2001087341A1 Agents for preventing or ameliorating insulin resistance and/or obesity
11/22/2001	WO2001087338A1 Immunomodulatory human mhc class ii antigen-binding polypeptides
11/22/2001	WO2001087337A1 Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
11/22/2001	WO2001087335A2 Method for selectively inhibiting ghrelin action
11/22/2001	WO2001087330A2 Compositions and methods for achieving immune suppression
11/22/2001	WO2001087294A1 Phosphate transport inhibitors
11/22/2001	WO2001087286A2 Antisense enzyme inhibitors for improving pharmacokinetics of a drug
11/22/2001	WO2001087284A2 Aldosterone antagonist composition for release during aldosterone acrophase
11/22/2001	WO2001087268A1 Micellar pharmaceutical compositions for buccal and pulmonary application
11/22/2001	WO2001087267A1 Protein matrix materials, devices and methods of making and using thereof
11/22/2001	WO2001087234A2 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers
11/22/2001	WO2001042246A3 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
11/22/2001	WO2001038355A3 Method of forming a peptide-receptor complex with zsig33 and therapeutic use thereof
11/22/2001	WO2001035995A3 Tr3-specific binding agents and methods for their use
11/22/2001	WO2001034119A3 Inhibitors of crystallization in a solid dispersion
11/22/2001	WO2001030781A3 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
11/22/2001	WO2001027268A3 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
11/22/2001	WO2001021795A3 Fatty acid transport proteins
11/22/2001	WO2001017211A3 Communications system
11/22/2001	US20010044937 Transgenic intracytoplasmic sperm injection, retroviral gene transfer, intracytoplasmic nuclear injection, and pronuclear injection; useful as models for human disease/diagnosis, assessing safety and efficiency of drug and gene therapy
11/22/2001	US20010044538 Mitogen-activated protein (MAP) kinase; treating inflammatory diseases; compounds such as 3-(4-fluorophenyl)-1-hydroxy-2-(pyridin-4-yl)-1H-pyrrolo(3,2-b)pyridine
11/22/2001	US20010044537 Inhibit human factor Xa; treating thrombotic activity; 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((2-(1,2 -dihydoxyethyl)-4-hydroxy-5-ethoxytetrahydrofuran-3-yl)oxy)-pyridin-2 -yl)oxy)4-hydroxybenzamidine
11/22/2001	US20010044536 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
11/22/2001	US20010044519 Bile sequestering polymer comprises a crosslinked, alkylated, cationic polyamine or polyallylamine homo- or co-polymer
11/22/2001	US20010044474 Hydrogel-driven layered drug dosage form
11/22/2001	US20010044471 Hydrogenation of racemic 6-alkoxy-1H-indene-1,2(3H)-dione-2-oxime, with chiral acid, resolution, alkylation, bromination, carboxamidation
11/22/2001	US20010044460 Ophthalmic compositions for treating ocular hypertension
11/22/2001	US20010044453 Combination drug therapy for glycolipid storage diseases
11/22/2001	US20010044442 Dimethoxy quinazolines for treating diabetes
11/22/2001	US20010044436 Bicyclic inhibitors of glycogen synthase kinase 3
11/22/2001	US20010044416 Administering an antigen and a CD4+ T helper (Th2) cell immunostimulatory nucleic acid mucosally or dermally to produce an antigen specific immune response; treating autoimmune diseases, cancer, infections
11/22/2001	US20010044144 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
11/22/2001	US20010044110 Inhibition of mal1
11/22/2001	US20010043950 Core of fluvastatin, hydroxypropyl methyl cellulose and optionally other excipients, dosage form is color-stable during storage
11/22/2001	US20010042936 Process for producing solid creatine dosage forms and dosage forms obtainable thereby
11/22/2001	DE10024319A1 New bis-acylguanidine compounds are subtype-1 cellular sodium ion-proton antiporter inhibitors useful e.g. for treating arrhythmia, angina pectoris, infarction and insulin-independent diabetes mellitus
11/22/2001	DE10020667A1 Neue Benzoxazin- und Benzothiazin-Derivate und deren Verwendung in Arzneimitteln New benzoxazine and benzothiazine derivatives and their use in medicaments
11/22/2001	CA2781858A1 Modulators of tnf-.alpha. signaling
11/22/2001	CA2410091A1 Piperidyindoles as serotonin receptor ligands
11/22/2001	CA2409740A1 Novel aryl, alkenyl, and alkynyl 4-dedimethylaminotetracycline desrivatives
11/22/2001	CA2409699A1 Novel polymorph v of torasemide
11/22/2001	CA2409437A1 Aldosterone antagonist composition for release during aldosterone acrophase
11/22/2001	CA2409068A1 Novel dual oxidases as mitogenic and endocrine regulators
11/22/2001	CA2408745A1 Anti-angiogenic polypeptides
11/22/2001	CA2408691A1 Compositions and methods for achieving immune suppression
11/22/2001	CA2408667A1 Phosphate transport inhibitors
11/22/2001	CA2408513A1 Immunomodulatory human mhc class ii antigen-binding polypeptides
11/22/2001	CA2408408A1 Modulators of tnf- alpha signaling
11/22/2001	CA2408360A1 Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
11/22/2001	CA2406013A1 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers
11/21/2001	EP1156123A1 Method for detecting a variation of GH1 as indicator of growth hormone dysfunction
11/21/2001	EP1156057A1 Malto-oligosaccharide derivatives and uses thereof
11/21/2001	EP1156054A1 Drugs containing phosphoric acid derivatives as the active ingredient
11/21/2001	EP1155699A1 Pharmaceutical and nutritional compositions comprising phytosterols, folic acid, cyanocobalamine, pyridoxine and alimentary fibers
11/21/2001	EP1155021A1 Hesperitin pro-forms with enhanced bioavailability
11/21/2001	EP1155015A1 Process for the production of tert-butyl (e)-(6-[2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl](4r,6s)-2,2-dimethyl[1,3]dioxan-4-yl)acetate
11/21/2001	EP1155010A1 Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s
11/21/2001	EP1155007A2 1,2-benzothiazepines for the treatment of hyperlipidemic diseases
11/21/2001	EP1155000A1 2-aminopyridines containing fused ring substituents
11/21/2001	EP1154988A1 Mevinolin derivatives
11/21/2001	EP1154983A1 Novel substituted 3-phenoxy and 3-phenylalkyloxy-2-phenyl-propylamines
11/21/2001	EP1154978A1 Soluble double metal salt of group ia and iia of (-) hydroxycitric acid
11/21/2001	EP1154801A1 Integration of transplanted neural progenitor cells into neural tissue of immature and mature dystrophic recipients
11/21/2001	EP1154774A1 Quinazoline derivatives as angiogenesis inhibitors
11/21/2001	EP1007085B1 Use of growth hormone in compositions for treating insulin resistance in the heart
11/21/2001	EP0998292B1 Method for inhibiting bone resorption
11/21/2001	EP0852469B1 Use of threonine for the treatment of phenylketonuria
11/21/2001	EP0832082B1 N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
11/21/2001	EP0659179B1 Benzo-fused lactams promote release of growth hormone
11/21/2001	EP0650480B1 1-arylsulphonyl-3-phenyl-1,4,5,6-tetrahydropyridazines
11/21/2001	CN1323348A Delivery system for porcine somatotropin
11/21/2001	CN1323346A TPL-2/COT kinase and methods of use
11/21/2001	CN1323220A Insulin preparations for pulmonary delivery containing menthol
11/21/2001	CN1323219A Stable concentrated insulin preparations for pulmonary delivery
11/21/2001	CN1323209A Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
11/21/2001	CN1322719A MYT1 kinase inhibitor
11/21/2001	CN1322574A Insulin B chain gene vaccine prepn
11/21/2001	CN1322572A Transforming growth factor-beta gene vaccine as diabetes and nephropathy preventing preparation
11/21/2001	CN1322563A Zhengtang capsule for treating diabetes
11/21/2001	CN1322543A Preparation of antilipemic medicine
11/21/2001	CN1322539A Diabetes-treating medicine preparing process with Chigenteng vane leaf
11/21/2001	CN1075113C Realignment protein of human digestive enzyme and process for their preparation

1 ... 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 ... 1298